AU2013366503B2 - Saturated nitrogen and N-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria - Google Patents

Saturated nitrogen and N-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria Download PDF

Info

Publication number
AU2013366503B2
AU2013366503B2 AU2013366503A AU2013366503A AU2013366503B2 AU 2013366503 B2 AU2013366503 B2 AU 2013366503B2 AU 2013366503 A AU2013366503 A AU 2013366503A AU 2013366503 A AU2013366503 A AU 2013366503A AU 2013366503 B2 AU2013366503 B2 AU 2013366503B2
Authority
AU
Australia
Prior art keywords
compound according
antibiotic
substituted
chosen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013366503A
Other languages
English (en)
Other versions
AU2013366503A1 (en
Inventor
Alain Baulard
Priscille Brodin
Benoit Deprez
Marion FLIPO
Lucie MAINGOT
Nicolas Willand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Lille 2 Droit et Santé
Original Assignee
Université Lille 2 Droit et Santé
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Lille 2 Droit et Santé filed Critical Université Lille 2 Droit et Santé
Publication of AU2013366503A1 publication Critical patent/AU2013366503A1/en
Application granted granted Critical
Publication of AU2013366503B2 publication Critical patent/AU2013366503B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2013366503A 2012-12-21 2013-12-20 Saturated nitrogen and N-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria Ceased AU2013366503B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1203548A FR3000065A1 (fr) 2012-12-21 2012-12-21 Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
FR12/03548 2012-12-21
PCT/EP2013/077732 WO2014096378A1 (fr) 2012-12-21 2013-12-20 Hétérocycles azotés saturés et n-acylés potentialisant l'activité d'un antibiotique actif contre les mycobactéries

Publications (2)

Publication Number Publication Date
AU2013366503A1 AU2013366503A1 (en) 2015-07-09
AU2013366503B2 true AU2013366503B2 (en) 2018-02-01

Family

ID=48521019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013366503A Ceased AU2013366503B2 (en) 2012-12-21 2013-12-20 Saturated nitrogen and N-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria

Country Status (23)

Country Link
US (1) US9957249B2 (enExample)
EP (1) EP2935212B1 (enExample)
JP (1) JP6515035B2 (enExample)
KR (1) KR20150138152A (enExample)
CN (1) CN104955804B (enExample)
AU (1) AU2013366503B2 (enExample)
BR (1) BR112015014279A2 (enExample)
CA (1) CA2895606A1 (enExample)
CL (1) CL2015001640A1 (enExample)
CR (1) CR20150319A (enExample)
EA (1) EA028076B1 (enExample)
FR (1) FR3000065A1 (enExample)
GE (2) GEAP201813844A (enExample)
IL (1) IL239504B (enExample)
MA (1) MA38275B1 (enExample)
MX (1) MX2015008029A (enExample)
PE (1) PE20151327A1 (enExample)
PH (1) PH12015501427A1 (enExample)
SG (1) SG11201504492UA (enExample)
TN (1) TN2015000202A1 (enExample)
UA (1) UA117922C2 (enExample)
WO (1) WO2014096378A1 (enExample)
ZA (1) ZA201503719B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
DK3668853T3 (da) * 2017-08-16 2021-12-06 Glaxosmithkline Ip Dev Ltd Nye forbindelser
US11253499B2 (en) 2017-08-16 2022-02-22 Glaxosmithkline Intellectual Property Development Limited Compounds
ES2899365T3 (es) * 2017-08-16 2022-03-11 Glaxosmithkline Ip Dev Ltd Compuestos novedosos
RU2767542C1 (ru) * 2021-05-24 2022-03-17 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов
CN117903039A (zh) * 2023-12-26 2024-04-19 苏州艾缇克药物化学有限公司 一种1-Boc-4-(2-羧基苯基)哌啶的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005783A1 (en) * 2008-07-08 2010-01-14 Boehringer Ingelheim International Gmbh Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors
WO2010044885A2 (en) * 2008-10-17 2010-04-22 Whitehead Institute For Biomedical Research Soluble mtor complexes and modulators thereof
WO2010063774A1 (en) * 2008-12-02 2010-06-10 Galderma Research & Development Novel 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
EP1118612A1 (en) * 2000-01-21 2001-07-25 Universita Degli Studi di Firenze Piperazine derivatives possesing nootropic activity
TW593556B (en) * 2002-12-27 2004-06-21 Ind Tech Res Inst Dichroic dye, composition thereof, and liquid crystal composition and liquid-crystal display element containing the same
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
FR2903405B1 (fr) * 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
TW200938203A (en) * 2007-12-17 2009-09-16 Intervet Int Bv Anthelmintic agents and their use
WO2009080432A2 (en) 2007-12-21 2009-07-02 Eth Zurich Composition for treatment of tuberculosis
US8912329B2 (en) 2009-06-25 2014-12-16 BioVersys AG Composition for treatment of tuberculosis
KR101179508B1 (ko) * 2010-06-24 2012-09-07 한국과학기술연구원 1,6-이치환-3-아미노-4,5,6,7-테트라하이드로-1Ｈ-피라졸로［3,4-ｃ］피리딘-7-온 화합물 및 이 화합물의 제조방법
WO2013060744A2 (en) 2011-10-25 2013-05-02 Universite De Droit Et De La Sante De Lille 2 Compounds having an ethr inhibiting activity - use of said compounds as drugs - pharmaceutical composition and product containing said compounds
EP2852585A1 (en) * 2012-05-11 2015-04-01 AbbVie Inc. Nampt inhibitors
PL2875003T3 (pl) 2012-07-20 2017-05-31 Bayer Pharma Aktiengesellschaft Nowe kwasy 5-aminotetrahydrochinolino-2-karboksylowe i ich zastosowanie
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005783A1 (en) * 2008-07-08 2010-01-14 Boehringer Ingelheim International Gmbh Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors
WO2010044885A2 (en) * 2008-10-17 2010-04-22 Whitehead Institute For Biomedical Research Soluble mtor complexes and modulators thereof
WO2010063774A1 (en) * 2008-12-02 2010-06-10 Galderma Research & Development Novel 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IRIKURA, T., ET AL, "New Analgetic Agents. V. 1-Butyryl-4-cinnamylpiperazine Hydrochloride and Related Compounds", JOURNAL OF MEDICINAL CHEMISTRY, 1968, Vol. 11, No. 4, pages 801 - 804 *
LI, G., ET AL, "Design and synthesis of 4-arylpiperidinyl amide and Narylpiperidin-3-yl-cyclopropane carboxamide derivatives.. .", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, Vol. 21, No. 4, pages 1236 -1242 *
ZHANG, Z., ET AL, "Highly efficient and practical phosphoramidite-copper catalysts for amination of aryl iodides and heteroaryl bromides with alkylamines and N(H)-heterocycles", TETRAHEDRON, 2006, Vol. 62, No. 18, pages 4435 - 4443 *

Also Published As

Publication number Publication date
MA38275A1 (fr) 2017-11-30
EA201590828A1 (ru) 2015-11-30
IL239504A0 (en) 2015-08-31
SG11201504492UA (en) 2015-07-30
US9957249B2 (en) 2018-05-01
BR112015014279A2 (pt) 2017-07-11
PH12015501427B1 (en) 2015-09-14
EP2935212B1 (fr) 2019-02-27
US20150307471A1 (en) 2015-10-29
HK1215254A1 (zh) 2016-08-19
PE20151327A1 (es) 2015-10-12
CR20150319A (es) 2015-09-14
WO2014096378A1 (fr) 2014-06-26
MA38275B1 (fr) 2018-09-28
PH12015501427A1 (en) 2015-09-14
EA028076B1 (ru) 2017-10-31
JP6515035B2 (ja) 2019-05-15
CN104955804A (zh) 2015-09-30
JP2016503778A (ja) 2016-02-08
CL2015001640A1 (es) 2016-01-29
EP2935212A1 (fr) 2015-10-28
ZA201503719B (en) 2016-11-30
FR3000065A1 (fr) 2014-06-27
GEP20186857B (en) 2018-06-11
MX2015008029A (es) 2015-10-30
IL239504B (en) 2018-10-31
GEAP201813844A (en) 2018-02-12
UA117922C2 (uk) 2018-10-25
CN104955804B (zh) 2018-02-09
KR20150138152A (ko) 2015-12-09
AU2013366503A1 (en) 2015-07-09
CA2895606A1 (fr) 2014-06-26
TN2015000202A1 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
JP6515035B2 (ja) マイコバクテリアに対して活性な抗生物質の活性を増強する飽和窒素及びｎ−アシル化複素環
AU2017210567B2 (en) Tricyclic benzoxaborole compounds and uses thereof
MY148566A (en) Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
CA2976308A1 (en) Benzoxaborole compounds and uses thereof
ATE482933T1 (de) Sulfopyrrolderivate
AU2013366494B2 (en) Spiroisoxazoline compounds having an activity potentiating the activity of an antibiotic
CA2963875A1 (en) Antibacterial benzothiazole derivatives
Li et al. Synthesis and in vitro antitubercular evaluation of novel sansanmycin derivatives
CA2970852A1 (en) Phosphopantetheine compounds alone or in combination with hmg-coa reductase inhibitors for lowering serum cholesterol and serum triglicerides
WO2001032164A1 (en) Inhibitor for 20-hete-yielding enzyme
RU94032285A (ru) Цефалоспориновые соединения, способ их получения, фармацевтическая композиция
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
EA201000832A1 (ru) Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции
HK1215254B (en) Saturated nitrogen and n-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria
IE62011B1 (en) Piperazine derivatives
CA3153724A1 (en) Benzyl amine-containing 5,6-heteroaromatic compounds useful against mycobacterial infection
HU0500730D0 (en) New 1,2-diaryl-heterocyclic compounds and their preparation
HK1219939B (en) Tricyclic benzoxaborole compounds and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired